Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib
Carcinoma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 367 (final count)
- Started
- Jan 9, 2019
- Main results expected
- Aug 23, 2024
- Fully finished
- Mar 31, 2027
- Results posted
- Feb 10, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Objective Response Rate (ORR) by Investigator Assessment; Target Population Analysis Set
Measured over: Time from randomization/first dose of study treatment to progression or last evaluable assessment in the absence of progressionuntil the end of the study, or an approximate maximum of 5.6 years
Objective Response Rate (ORR) by Investigator Assessment; 300 mg QD Safety Analysis Set
Measured over: Time from randomization/first dose of study treatment to progression or last evaluable assessment in the absence of progression until the end of the study, or an approximate maximum of 5.6 years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT03778229 · record last updated 2026-11-02 · checked 2026-11-09 15:47 UTC